Trial Profile
Randomized Phase 2 Study Of PF-05212384 Plus Irinotecan Versus Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Gedatolisib (Primary) ; Cetuximab; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 16 Jul 2016 This trial has been completed in Belgium (2016-04-06) as per European Clinical Trials Database record.
- 04 Apr 2016 Planned End Date changed from 1 May 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
- 04 Apr 2016 Planned primary completion date changed from 1 May 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov record.